About the 9th Annual ELSCEO Forum & Exhibition

The 9th Annual ELSCEO Forum & Exhibition, is being held on 15th-16th March 2016 at the Hilton Zurich Airport Hotel, Switzerland. This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. We expect around 350 delegates and 80 presenting companies. Event's networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive.
Plenary Discussion Sessions include:
  • Public Markets and M&A
  • Investment [2 sessions on Early & Late Stage]
  • Partnering
  • Israel
  • Specific Therapeutic Panels on:​​
    • Autoimmune & Inflammatory
    • ​Diagnostics
    • ​MedTech & Digital Health
    • Neuroscience
    • Oncology I - Clinical Development and Regulation in Europe
    • Oncology II - Innovation and BD&L
    • Platform Technologies & Novel Therapeutics
Confirmed Speakers & Chairs include:
  • Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd. 
  • Anja König, Managing Director, Novartis Venture Fund
  • Anker Lundemose, CEO, MISSION Therapeutics Ltd.
  • Arthur Franken, Partner, Gilde Healthcare
  • Bart de Witte, Government & Healthcare Leader CEE, IBM 
  • Beat Merz, Managing Director, Rockport Venture Partners
  • Bill Blair, Director Company Creation, Sunergos Innovations​​
  • Carina Schmidt, CEO, Athera Biotechnologies AB
  • Chandra Leo, Partner, HBM Partners AG
  • Charles Bailey, Head of Search & Evaluation, Neurosciences, Novartis Pharma AG
  • Chris Britten, Managing Director, Torreya Partners Europe LLP 
  • Christophe Bonny, CSO, Bicycle Therapeutics Limited
  • Christian Lach, Portfolio Manager, Bellevue Asset Management AG
  • Chris Maggos, Managing Director, Europe, LifeSci Advisors
  • Cynthia Lavoie, General Partner, TVM Life Science Management, Inc. 
  • Dale Dhanoa, CEO, AKAAL Pharma
  • ​Dan Jacob Gelvan, Managing Director, Aurum Ventures MKI Ltd.
  • David Cassak, Managing Partner, Innovation in Medtech, LLC
  • David Colpman, Director, Colpman Consulting Ltd.
  • David Malek, VP Business Development, BioLineRx
  • David Reese, President and CEO, Provista Diagnostics, Inc. 
  • David Urech, Co-CEO & CSO, Numab AG
  • David Schubert, CIO, Accelerator Corporation
  • ​Dieter Ziegler, Director - Search and Evaluation Europe, AbbVie Inc.
  • Donnie McGrath, VP, Search & Evaluation, Business Development, Bristol-Myers Squibb
  • Ekaterina Smirnyagina, Partner, Capricorn Venture Partners NV 
  • Ena Prosser, Partner, Fountain Healthcare Partners
  • Eric de La Fortelle, Venture Partner, Seventure Partners
  • Eric Rambeaux, CEO, MyoPowers Medical Technologies France SAS
  • Erik van den Berg, CEO, AM-Pharma
  • Ernst Hafen, President, BIO-TECHNOPARK, Schlieren-Zurich
  • Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics
  • Eugen Leo, Senior consultant, LEOconsulting
  • Fabian Buller, Director, New Ventures, Johnson & Johnson Innovation
  • ​Fintan Walton, CEO, PharmaVentures Ltd.
  • François Thomas, President, Inserm Transfert Initiative
  • Geoff Cumming, CEO, Anteo Diagnostics Limited
  • Guillaume Vignon, Director BD Oncology - Global Business Development and Licensing, EMD Serono 
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Heinz Lubenau, General Manager and Head of Development, VAXIMM GmbH
  • Heinz Schwer, CEO, Lanthio Pharma B.V. 
  • Ivana Magovcevic-Liebisch, Senior Vice President and Head of Global Business Development, Teva Pharmaceutical Industries, Ltd.
  • Isabella Schidrich, Managing Director, NASDAQ
  • Ittai Harel, Managing General Partner, Pitango Venture Capital
  • Ivo Staijen, Investment Advisor/Portfolio Manager, HBM Partners AG 
  • James Sapirstein, CEO, ContraVir Pharmaceuticals
  • ​Jane Atkins, Director, Search & Evaluation, Takeda Pharmaceuticals International GmbH
  • Jason Slingsby, Head of Business Development, Oxford BioMedica Plc.
  • Jennifer McMahon, Associate,  Seroba Life Sciences
  • ​Jenny Laird, Senior Director, Search & Evaluation, Eli Lilly & Co.
  • Joern-Peter Halle, SVP, Head of External Innovation, Biopharma, Global Research & Development, Merck
  • Jonathan Tobin, Principal, Healthcare Ventures, Imperial Innovations
  • Karl Nägler, Partner, Gimv
  • Klaus Mendla, Global Head, BD and Licensing CNS, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Lars Gredsted, Senior Business Analyst, Wellcome Trust
  • Laurence Barker, Dementia Discovery Fund Chief Business, SV Life Sciences
  • Laurent Audoly, Senior Vice President R&D, Global Head of Drug Development and Translational Medicine,
    ​Institut de Recherche Pierre Fabre
  • Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
  • Lionel Carnot, Managing Director, Bay City Capital 
  • Lubor Gaal, Head of Licensing and External Innovation, Almirall, S.A.
  • Luisa Henk, ‎Officer, Drooms AG
  • Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie, Inc.
  • Mark Vaeck, CEO, Complix NV
  • Markus Goebel, Managing Director, Novartis Venture Fund
  • Markus Hosang, General Partner and Managing Director, BioMedPartners AG
  • Markus Kalousek, Global BD&L Franchise Head, I&D, S&E, Novartis Pharma AG
  • Mark Carnegie-Brown, CEO, Glide Technologies
  • Martin Pfister, Senior Investment Manager, High-Tech-Gruenderfonds Management GmbH
  • Matthew Foy, Partner, S.R.One, Limited
  • Matthias Bünte, Head Operational Transaction Services, Ernst & Young AG
  • Michal Silverberg, Senior Director, External Innovations, Israel and Europe, Takeda Pharmaceuticals
  • Michele Ollier, Partner, Medicxi Ventures
  • Nanna Luneborg, Principal, Novo Ventures 
  • Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners
  • Norbert Steinbach, Director Business Development Western Europe & Canada, AbbVie Inc.
  • Oliver Schacht, CEO, Curetis N.V.
  • Paola Casarosa, Corp. VP, Business Development & Licensing/Prescription Medicines, Boehringer Ingelheim GmbH
  • Patrick Benz, Senior Director Alliance Management, Johnson & Johnson Innovation/JBD
  • Paul Hermant, Partner, Bird & Bird LLP
  • Peter Hoang, Senior Vice President, Business Development & Strategy​, Bellicum Pharmaceuticals, Inc.
  • Peter Langkafel, CEO, HCB Healthcubator GmbH 
  • Raffaele Petrone, Chairman of Board of Directors and CEO, Therametrics
  • Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH
  • Rao Movva, Novartis Distinguished Scientist, Novartis Institutes for BioMedical Research
  • Regina Hodits, General Partner, Wellington Partners
  • Reza Halse, ‎Head of MSD European Innovation Hub, MSD
  • Richard Godfrey, CEO, BerGenBio AS
  • Rosa Sancho, Head of Research, Alzheimer's Research UK
  • Ruth Ben Yakar, CEO, BioSight Ltd.
  • Sandra Nobre, Senior Director Business Development, Takeda Pharmaceuticals International
  • Sarah Holland, Head of Europe, External Science and Partnering, Sanofi
  • Simon Blake, Senior Director, Scientific Licensing for Immunology, Johnson & Johnson
  • Simon Kerry, Chief Executive Officer, Karus Therapeutics Ltd.
  • Stephanie Léouzon, Partner and Head of Europe, Torreya Partners (Europe) LLP
  • Stephen Levin, Managing Partner, Innovation in Medtech, LLC
  • Stewart Kay, Director, Business Development, GSK
  • TBC, Drooms
  • Thierry Chignon, Senior Partner, Merieux Developpement 
  • Thomas Stockman, Director, Healthcare Investment Banking, Royal Bank of Canada
  • Thomas Wilckens, CEO, InnVentis Ltd.
  • Tim Dyer, CEO, Addex Therapeutics
  • Tim Herpin, Vice President, Head of Transactions (UK), AstraZeneca
  • Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
  • Ulrich Muehlner, Global Head Outcomes Technologies Incubator (NOVAE), Novartis
  • Uwe Schoenbeck, ‎SVP & Chief Scientific Officer, External R&D, Pfizer
  • Yves Decadt, CEO, Medimetrics Personalized Medicine
Presenting Opportunities:

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering. The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners.
To view confirmed presenting companies for 2016 forum click HERE
Exhibitors in 2016 include:

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
​
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact:
​
Silvia Kar on + 44 (0)203 463 4890 or by email: Silvia.
Silver Sponsors:
Supported by:
Pharma Licensing Groups ​Attending in 2016 Include:
Financial
Advisory/Investors 
Confirmed for 2016:​
AAIPharma Services Corp. | Cambridge Major Laboratories, Inc.
Affas Besse Advisors Ltd.
Austin Life Science Partners AG
BioLife Solutions, Inc
BioStart Consulting GmbH
Bird & Bird LLP
Bootstrap Europe
Breslin AG
Capricorn One
Colpman Consulting Ltd.
Corinthian Financial Management Ltd.
Ernst & Young AG
FreeMind Group
goetzpartners holding
Grabulovski Consulting Services
Health Advances GmbH
High Beacon Ltd.
inVentiv Health, Inc.
Inventiva Pharma
IPSA
LifeCare Partners
MC Services AG
Mediatum Schweiz GmbH
RSA AG
The Trout Group
XOventure GmbH
AGLAIA BioMedical Ventures B.V.
ALSTIN
Amorchem
Aravis SA
Arcus Ventures
Aurum Holdings MKI Ltd.
Bay City Capital LLC
BB Biotech Ventures
Beechwood Ventures
Bellevue Asset Management AG
Belmont Capital
Belsize Asset Management
BioBac BioValley Business Angels Club
BioMedPartners AG
Boehringer Ingelheim GmbH Venture Fund
Brean Capital, LLC
Brock Capital Group LLC
ChinaBio Capital
Cukierman & Co. Life Sciences
Deca Ventures
Eckert Life Science Accelerator GmbH (ELSA)
Edison
Edmond de Rothschild Investment Partners
EMD Serono
Enso Ventures
Forbion Capital Partners
Fountain Healthcare Partners
Fraser Finance
Fukoku Life International (UK) Ltd.
fundamenta CAPITAL AG
Gilde Healthcare
GIMV
Global Life Science Ventures
HBM Partners AG
HCB Healthcubator GmbH
HealthCare Royalty Partners
Helvea Baader Bank
High-Tech Gruenderfonds Management GmbH
IBM
Imperial Innovations
Industrifonden
INKEF Capital BV
InSymbiosis Capital
Inveready
Kreos Capital
MainFirst
Medicxi Ventures
MedVenture Partners GmbH
Merchant Liquidity Fund, LP
MPM Capital
MS Ventures
Nasdaq
Neomed
Nextech Invest Ltd.
Omega Funds
Oppenheimer & Co., Inc.
Peppermint Venture Partners GmbH
PharmaVentures Ltd.
Pitango Venture Capital
PM Equity Partner
RBV Capital
Redalpine Venture Partners
RMI Partners
Rockport Venture Partners
Rodman & Renshaw, LLC
Rosetta Capital Ltd
Royal Bank of Canada
S.R.One, Limited
Seroba Life Sciences
Seventure Partners
Sirius Healthcare Partners
SIX Swiss Exchange
Skolkovo Foundation
SMR Consulting GmbH
SNS Securities
Sofinnova Partners
Stanphyl Capital
Sunstone Capital A/S
Sunstone Life Science Ventures
SV Life Sciences
The Fulford Group
Thuja Capital B.V.
Torreya Partners (Europe), LLP
TVM Capital China Limited
TVM Life Science Management Inc.
Ventac Partners
VI Partners AG
Visium Asset Management
Vogel BioC
Wellcome Trust
Wellington Partners
Wingspan Ventures
Yorkville Advisors, LLC
Ysios Capital Partners
Zukunftsfonds Heilbronn GmbH & Co KG

For information about the last year's forum including speakers, presenting companies, financials/advisors/investors attending and more click HERE